New all oral therapy for chronic hepatitis C virus (HCV): A novel long-term cost comparison

Cost Effectiveness and Resource Allocation

Volumn 13, Issue 1, 2015, Pages

  Poonsapaya, Jennifer M ^a   Einodshofer, Michael ^a   Kirkham, Heather S ^a   Glover, Pheophilus ^b   DuChane, Janeen ^a  

^a Walgreen   (United States)

^b Baxalta US Inc   (United States)

Author keywords

All oral therapy; Antiviral agents; Cost savings analysis; Economic modeling; Hepatitis c prevalence; Hepatitis c treatment; Hepatitis c virus; Interferon; Managed care

Indexed keywords

ANTIRETROVIRUS AGENT; BOCEPREVIR; LEDIPASVIR; PEGINTERFERON; RIBAVIRIN; SOFOSBUVIR; TELAPREVIR; VIRUS ANTIBODY;

ADULT; AGED; ANEMIA; ARTICLE; CONTROLLED STUDY; COST CONTROL; DEPRESSION; DISEASE COURSE; DRUG COST; DRUG TOLERABILITY; DRUG UTILIZATION; ECONOMIC ASPECT; FEMALE; FLU LIKE SYNDROME; GENOTYPE; HEALTH CARE COST; HEALTH CARE QUALITY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; POPULATION SIZE; PREVALENCE; RASH; RISK FACTOR; SENSITIVITY ANALYSIS; SEROPREVALENCE; SLEEP DISORDER; UNITED STATES; VERY ELDERLY;

EID: 84943584734     PISSN: None     EISSN: 14787547     Source Type: Journal    
DOI: 10.1186/s12962-015-0043-y     Document Type: Article

References (48)

1. Sexually transmitted diseases treatment guidelines. 2010. [ http://www.cdc.gov/std/treatment/2010/hepC.htm ]. Accessed 19 Sep 2013.
2. Hepatitis C FAQs for Health Professionals. [ http://www.cdc.gov/hepatitis/HCV/HCVfaq.htm ]. Accessed 19 Sep 2013.
3. Moyer VA, U.S. Preventive Services Task Force. Screening for hepatitis C virus infection in adults: US Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2013;159:349-357.
4. Klevens RM, Hu DJ, Jiles R, Holmberg SD. Evolving epidemiology of hepatitis C virus in the United States. Clin Infect Dis. 2012;55(Suppl 1):S3-9.
5. Blatt LM, Mutchnick MG, Tong MJ, Klion FM, Lebovics E, Freilich B, Bach N, Smith C, Herrera J, Tobias H, et al. Assessment of hepatitis C virus RNA and genotype from 6807 patients with chronic hepatitis C in the United States. J Viral Hepat. 2000;7:196-202.
6. Spradling PR, Rupp L, Moorman AC, Lu M, Teshale EH, Gordon SC, Nakasato C, Boscarino JA, Henkle EM, Nerenz DR, et al. Hepatitis B and C virus infection among 1.2 million persons with access to care: factors associated with testing and infection prevalence. Clin Infect Dis. 2012;55:1047-55.
7. Hagan H, Campbell J, Thiede H, Strathdee S, Ouellet L, Kapadia F, Hudson S, Garfein RS. Self-reported hepatitis C virus antibody status and risk behavior in young injectors. Public Health Rep. 2006;121:710-9.
8. Afdhal NH. The natural history of hepatitis C. Semin Liver Dis. 2004;24(Suppl 2):3-8.
9. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology. 2010; 138:513-521, 521 e511-516.
10. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49:1335-74.
11. American Association for the Study of Liver Diseases and the Infectious Diseases Society of America. Monitoring patients who are starting hepatitis C treatment, are on treatment, or have completed therapy. In: Recommendations for testing, managing, and treating Hepatitis C. 2014. [ http://www.hcvguidelines.org/full-report-view ]. Accessed 16 March 2015.
12. European Public Assessment Report. PegIntron [ http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000280/WC500039388.pdf ]. Accessed 7 Feb 2014.
13. Biologics License Application Supplement: PEGASYS. [ http://www.accessdata.fda.gov/drugsatfda_docs/label/2002/pegihof120302LB.htm#desc ]. Accessed 7 Feb 2014.
14. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54:1433-44.
15. DailyMed: Current medication information. [ http://dailymed.nlm.nih.gov/dailymed ]. Accessed 31 July 2014.
16. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975-82.
17. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958-65.
18. Younossi ZM, Singer ME, Mir HM, Henry L, Hunt S. Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients. J Hepatol. 2014;60:530-7.
19. New guidelines expected to help clinicians sort out hepatitis C treatment options. [ http://newsatjama.jama.com/2014/01/30/new-guidelines-expected-to-help-clinicians-sort-out-hepatitis-c-treatment-options/ ]. Accessed 31 July 2014.
20. Hagan LM, Yang Z, Ehteshami M, Schinazi RF. All-oral, interferon-free treatment for chronic hepatitis C: cost-effectiveness analyses. J Viral Hepat. 2013;20:847-857.
21. FDA Approves 'Game Changer' Hepatitis C Drug Sofosbuvir. [ http://www.medscape.com/viewarticle/817371 ]. Accessed 13 March 2014.
22. The majority of physicians that treat hepatitis C virus (HCV) have begun "Warehousing" and preparing their HCV patients for the next generation of HCV treatments. [ http://bio-trends.com/News-and-Events/Press-Releases/TreatmentTrends-Hepatitis-C-Virus-052313 ]. Accessed 15 March 2015.
23. FirstWord Pharma. Physician views: what opportunity for Gilead Sciences' hepatitis c therapy sofosbuvir before interferon-sparing regimens reach the market? In: Physician Views Desk. 2013.
24. BioTrends Research Group. The majority of physicians that treat hepatitis c virus (HCV) have begun "warehousing" and preparing their HCV patients for the next generation of HCV treatments. 2013.
25. FirstWord Pharma. ViewPoints: Identifying the unidentified-the hepatitis c market and patient warehousing. 2012.
26. Gilead announces US FDA priority review designation for ledipasvir/sofosbuvir fixed-dose combination tablet for chronic hepatitis C genotype 1 infection. [ http://www.gilead.com/news/press-releases/2014/4/gilead-announces-us-fda-priority-review-designation-for-ledipasvirsofosbuvir-fixeddose-combination-tablet-for-chronic-hepatitis-c-genotype-1-infection ]. Accessed 31 July 2014.
27. McQuillan GM, MD, Denniston MM, Hirsch R. Viral hepatitis. In: NCHS data brief (Statistics NCfH ed. Hyattsville, MD: US. 2010.
28. Viral hepatitis statistics and surveillance. [ http://www.cdc.gov/hepatitis/statistics/ ]. Accessed 30 Nov 2013.
29. US Census Bureau. 2012 American community survey: 1-year estimate (S0101) using American FactFinder. vol. 2013.
30. US Census Bureau. Population distribution and change: 2000-2010. In: 2010 census briefs. 2011.
31. State and County QuickFacts. District of Columbia. [ http://quickfacts.census.gov/qfd/states/11000.html ]. Accessed 9 April 2014.
32. Resident population data (text version). [ http://www.census.gov/2010census/data/apportionment-dens-text.php ]. Accessed 9 April 2014.
33. Moyer VA. Screening for hepatitis C virus infection in adults: US preventive services task force recommendation statement. Ann Intern Med. 2013;159:349-57.
34. Volk ML, Tocco R, Saini S, Lok AS. Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology. 2009;50:1750-5.
35. Biomed Tracker. Cost of anticipated all oral therapy for genotype 1 chronic hepatitis C virus: sofosbuvir/ledipasvir combination. e-mail communication edition. 2014.
36. Prognosis in decompensated chronic liver failure. Fast facts and concepts. [ http://www.eperc.mcw.edu/EPERC/FastFactsIndex/ff_189.htm ]. Accessed 25 Sep 2013.
37. Manos MM, Darbinian J, Rubin J, Ray GT, Shvachko V, Denis B, Velez F, Quesenberry C. The effect of hepatitis C treatment response on medical costs: a longitudinal analysis in an integrated care setting. J Manag Care Pharm. 2013;19:438-47.
38. Consumer Price Index. CPI databases: All urban consumers (current series). [ http://www.bls.gov/cpi/data.htm ]. Accessed 11 Oct 2013.
39. Gordon SC, Pockros PJ, Terrault NA, Hoop RS, Buikema A, Nerenz D, Hamzeh FM. Impact of disease severity on healthcare costs in patients with chronic hepatitis C (CHC) virus infection. Hepatology. 2012;56:1651-60.
40. Centers for Medicare and Medicaid Services: NHE Projections 2012-2022.
41. Sherman KE. Therapeutic approach to the treatment-naive patient with hepatitis C virus genotype 1 infection: a step-by-step approach. Clin Infect Dis. 2012;55:1236-41.
42. Younossi ZM, Singer ME, Mir HM, Henry L, Hunt S. Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients. J Hepatol. 2014;60:530-7.
43. Colvin HM, Mitchell AE. Hepatitis and liver cancer: a national strategy for prevention and control of hepatitis B and C. National Academies Press. 2010.
44. Gilead announces SVR12 rates from three phase 3 studies evaluating a once-daily fixed-dose combination of sofosbuvir and ledipasvir for genotype 1 hepatitis C patients. [ http://www.gilead.com/news/press-releases/2013/12/gilead-announces-svr12-rates-from-three-phase-3-studies-evaluating-a-oncedaily-fixeddose-combination-of-sofosbuvir-and-ledipasvir-for-genotype-1-hepatitis-c-patients ]. Accessed 7 Jan 2014.
45. Sovaldi. Highlights of prescribing information. [ http://www.gilead.com/~/media/Files/pdfs/medicines/liver-disease/sovaldi/sovaldi_pi.pdf ]. Accessed 7 Jan 2014.
46. FastStats. Body measurements. [ http://www.cdc.gov/nchs/fastats/bodymeas.htm ]. Accessed 10 April 2014.
47. PR Newswire. A significant share of surveyed treatment-naive and prior failure HCV patients plan to initiate an HCV treatment regimen in the next year. PR Newswire. 2013.
48. Yee HS, Chang MF, Pocha C, Lim J, Ross D, Morgan TR, Monto A. Update on the management and treatment of hepatitis C virus infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office. Am J Gastroenterol. 2012;107:669-89 (quiz 690).